KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Rigel Pharmaceuticals (RIGL) Other Gross PP&E Adjustments (2016 - 2025)

Rigel Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 15 years, most recently at -$573000.0 for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 635.51% year-over-year to -$573000.0; the TTM value through Dec 2025 reached -$573000.0, down 635.51%, while the annual FY2025 figure was -$573000.0, 635.51% down from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was -$573000.0 at Rigel Pharmaceuticals, up from -$1.0 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $9.7 million in Q4 2022 and troughed at -$15.9 million in Q1 2021.
  • A 5-year average of -$2.4 million and a median of -$1.0 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 366.2% in 2021 and later plummeted 635.51% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at $6.8 million in 2021, then soared by 42.56% to $9.7 million in 2022, then plummeted by 89.64% to $1.0 million in 2023, then tumbled by 89.38% to $107000.0 in 2024, then plummeted by 635.51% to -$573000.0 in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for RIGL at -$573000.0 in Q4 2025, -$1.0 million in Q3 2025, and -$1.2 million in Q2 2025.